Library
3-MeO-PCMo
3-MeO-PCMo is a dissociative anesthetic of the arylcyclohexylamine class, specifically a morpholine analogue of 3-MeO-PCP. It functions as an NMDA receptor antagonist and sigma receptor agonist, producing a state of dissociative anesthesia. Notably, it possesses less than one-tenth the potency of its parent compound 3-MeO-PCP. It has appeared on the research chemical market as a designer drug with very limited data regarding its safety profile or long-term effects.
Also known as: Pcmo, 3-methoxy-PCMo
Classification
- Chemical: Arylcyclohexylamine
- Psychoactive: Dissociative
- Tag: Morpholine derivative
- Tag: Research-Chemical
- Tag: Tentative
Effects
- Spontaneous Tactile Sensations
- Nausea
- Physical Euphoria
- Tactile Disconnection
- Physical Disconnection
- Spontaneous Bodily Sensations
- Depersonalization
- Derealization
- Consciousness Disconnection
- Memory Suppression
- Thought Deceleration
- Immersion Enhancement
- Disinhibition
- Tactile Suppression
- Hallucinations
- Visual Disconnection
- Double Vision
- Pattern Recognition Suppression
Routes of Administration
Oral
Dosage
- Heavy: 220+ mg
- Light: 50 – 80 mg
- Common: 80 – 125 mg
- Strong: 125 – 150 mg
- Threshold: 30-60 mg
Duration
- Onset: 0.5-1 h
- Peak: 2-3 h
- Offset: 1-2 h
- After Effects: 2-12 h
- Total Duration: 3-5 h
Insufflated
Dosage
- Heavy: 220+ mg
- Light: 50-100 mg
- Common: 100-160 mg
- Strong: 160-220 mg
- Threshold: 30-50 mg
Duration
- Onset: 0.17-0.42 h
- Peak: 1-2 h
- Offset: 2-3 h
- After Effects: 2-12 h
- Total Duration: 3-4 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
